Randomized phase II study of vandetanib (V), docetaxel (D), and carboplatin (C) followed by maintenance V or placebo (P) in patients with stage IIIb, IV, or recurrent non-small cell lung cancer (NSCLC): PrECOG PrE0501-Update on maintenance treatment, progression-free survival (PFS), and overall survival (OS).

被引：4
|
作者：
Aisner, J.
Manola, J.
Dakhil, S. R.
Stella, P. J.
Schiller, J. H.
机构：
[1] Canc Inst New Jersey, New Brunswick, NJ USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Wichita Community Clin Oncol Program, Wichita, KS USA
[4] St Joseph Mercy Hlth Syst, Ann Arbor, MI USA
[5] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.7560
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7560
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Vandetanib, docetaxel and carboplatin followed by maintenance vandetanib or placebo in patients with stage IIIB, IV or recurrent non-small cell lung cancer (NSCLC): a randomized phase II study (PrE0502) by PrECOG, LLC (NCT006872970)
    Aisner, J.
    Manola, J.
    Dakhil, S.
    Stella, P.
    Schiller, J.
    EJC SUPPLEMENTS, 2010, 8 (07): : 130 - 130
  • [2] OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) RESULTS FOR A RANDOMIZED PHASE 2 TRIAL OF IPILIMUMAB (IPI) AND PACLITAXEL/CARBOPLATIN (P/C) IN FIRST-LINE STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC)
    Lynch, T. J., Jr.
    Neal, J.
    Bondarenko, I.
    Luft, A.
    Serwatowski, P.
    Barlesi, F.
    Chacko, R.
    Sebastian, M.
    Cuillerot, J.
    Reck, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 126 - 126
  • [3] Vandetanib Plus Chemotherapy for Induction Followed by Vandetanib or Placebo As Maintenance for Patients with Advanced Non-Small-Cell Lung Cancer: A Randomized Phase 2 PrECOG Study (PrE0501)
    Aisner, Joseph
    Manola, Judith B.
    Dakhil, Shaker R.
    Stella, Philip J.
    Sovak, Mika A.
    Schiller, Joan H.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (08) : 1075 - 1083
  • [4] Progression-free survival (PFS) and overall survival (OS) in phase HI trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Hotta, K.
    Kiura, K.
    Takigawa, N.
    Tabata, M.
    Fujiwara, Y.
    Tanimoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] VANDETANIB PLUS CHEMOTHERAPY FOR INDUCTION THERAPY FOLLOWED BY VANDETANIB OR PLACEBO AS MAINTENANCE FOR ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): EFFICACY AND TOXICITIES UPDATE. A PHASE II PRECOG, LLC STUDY (PRE0501)
    Aisner, Joseph
    Manola, Judith
    Dakhil, Shaker
    Stella, Phillip J.
    Schiller, Joan
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1258 - S1258
  • [6] Overall Survival and Progression Free Survival Results for a Randomized Phase 2 Trial of Ipilimumab (IPI) and Paclitaxel/Carboplatin (P/C) in First-Line Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
    Lynch, T. J.
    Neal, J.
    Bondarenko, I.
    Luft, A.
    Serwatowski, P.
    Barlesi, F.
    Chacko, R.
    Sebastian, M.
    Cuillerot, J.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S515 - S515
  • [7] OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE
    Heron, L.
    De Castro Carpeno, J.
    Chouaid, C.
    Vergnenegre, A.
    Bischoff, H. G.
    Walzer, S.
    VALUE IN HEALTH, 2011, 14 (03) : A177 - A178
  • [8] OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE
    Heron, Louise
    Chouaid, Christos
    Vergnenegre, Alain
    Bischoff, Helge
    Walzer, Stefan
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1447 - S1448
  • [9] Mature Progression-Free Survival in Stage IV Non-Small Cell Lung Cancer Patients Treated With Pemetrexed Maintenance Therapy
    Bhatt, P.
    Bonomi, P.
    Basu, S.
    Batus, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S868 - S869
  • [10] Influence of crossover therapy on the association between progression-free survival (PFS) and overall survival (OS) in randomized trials of molecular-targeted agents for advanced non-small cell lung cancer (NSCLC).
    Hotta, K.
    Kiura, K.
    Suzuki, E.
    Takigawa, N.
    Fujiwara, Y.
    Ichihara, E.
    Tabata, M.
    Tanimoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345